[AstraZeneca's breast cancer treatment trial did not meet expectations] AstraZeneca announced that the experimental anti-cancer drug Dato DXD, which was jointly developed with Daiichi Sankyo, failed to extend the survival period of patients in a key breast cancer treatment trial, and had no significant advantage over chemotherapy. The company stated that it will share these trial results with regulatory agencies and explore whether the drug should be approved for marketing.